Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (Estrogen Receptor [ER] and/or Progesterone Receptor [PR] +) Human Epidermal Growth Factor Receptor 2 (HER-2) Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2016
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Dec 2015 Status changed from active, no longer recruiting to completed according to results presented at the 38th Annual San Antonio Breast Cancer Symposium.
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
- 23 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.